{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:09:10Z","timestamp":1765357750786,"version":"build-2065373602"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009192","name":"Alberta Innovates","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000190","name":"University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019691","name":"Faculty of Medicine and Dentistry, University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010090","name":"Women and Children's Health Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023851","name":"Institut de Myologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014407","name":"Ministry of Advanced Education, Government of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000223","name":"Muscular Dystrophy Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.omtn.2024.102443","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T11:35:26Z","timestamp":1734780926000},"page":"102443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antisense oligonucleotide-mediated exon 27 skipping restores dysferlin function in dysferlinopathy patient-derived muscle cells"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3688-5923","authenticated-orcid":false,"given":"Saeed","family":"Anwar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohini Roy","family":"Roshmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Woo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umme Sabrina","family":"Haque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua James","family":"Arthur Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William John","family":"Duddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Bigot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7316-3546","authenticated-orcid":false,"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2024.102443_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/1689","article-title":"A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B","volume":"20","author":"Bashir","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2024.102443_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/1682","article-title":"Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy","volume":"20","author":"Liu","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2024.102443_bib3","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41436-019-0544-8","article-title":"Estimating prevalence for limb-girdle muscular dystrophy based on public sequencing databases","volume":"21","author":"Liu","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtn.2024.102443_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000369343","article-title":"Prevalence of muscular dystrophies: A systematic literature review","volume":"43","author":"Theadom","year":"2014","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.omtn.2024.102443_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/cjn.2015.311","article-title":"A Systematic Review and Meta-analysis on the Epidemiology of the Muscular Dystrophies","volume":"43","author":"Mah","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.omtn.2024.102443_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.2236","article-title":"Genetic screening of an endemic mutation in the DYSF gene in an isolated, mountainous population in the Republic of Dagestan","volume":"11","author":"Bardakov","year":"2023","journal-title":"Mol. Genet. Genomic Med."},{"key":"10.1016\/j.omtn.2024.102443_bib7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/biom14030256","article-title":"The Dysferlinopathies Conundrum: Clinical Spectra, Disease Mechanism and Genetic Approaches for Treatments","volume":"14","author":"Anwar","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.omtn.2024.102443_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1212\/WNL.57.2.271","article-title":"Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy","volume":"57","author":"Aoki","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2024.102443_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/cge.14216","article-title":"Dysferlinopathies: Clinical and genetic variability","volume":"102","author":"Ivanova","year":"2022","journal-title":"Clin. Genet."},{"key":"10.1016\/j.omtn.2024.102443_bib10","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/0960-8966(96)88958-9","article-title":"The phenotype of chromosome 2P-linked limb-girdle muscular dystrophy","volume":"6","author":"Mahjneh","year":"1996","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2024.102443_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/1531-8249(200101)49:1<130::AID-ANA22>3.0.CO;2-0","article-title":"Distal anterior compartment myopathy: A dysferlin mutation causing a new muscular dystrophy phenotype","volume":"49","author":"Illa","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2024.102443_bib12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/mus.880100411","article-title":"High serum levels of creatine kinase: Asymptomatic prelude to distal myopathy","volume":"10","author":"Galassi","year":"1987","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtn.2024.102443_bib13","series-title":"GeneReviews\u00ae [Internet]","first-page":"NBK1303","article-title":"Dysferlinopathy","author":"Aoki","year":"2021"},{"key":"10.1016\/j.omtn.2024.102443_bib14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/humu.20642","article-title":"Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients","volume":"29","author":"Guglieri","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2024.102443_bib15","doi-asserted-by":"crossref","first-page":"E345","DOI":"10.1002\/humu.20910","article-title":"Analysis of the DYSF mutational spectrum in a large cohort of patients","volume":"30","author":"Krahn","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2024.102443_bib16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.4103\/0028-3886.149386","article-title":"Clinical heterogeneity and a high proportion of novel mutations in a chinese cohort of patients with dysferlinopathy","volume":"62","author":"Xi","year":"2014","journal-title":"Neurol. India"},{"key":"10.1016\/j.omtn.2024.102443_bib17","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneur.64.8.1176","article-title":"Phenotypic study in 40 patients with dysferlin gene mutations: High frequency of atypical phenotypes","volume":"64","author":"Nguyen","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.omtn.2024.102443_bib18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/humu.9355","article-title":"Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies","volume":"26","author":"Nguyen","year":"2005","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2024.102443_bib19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nature01573","article-title":"Defective membrane repair in dysferlin-deficient muscular dystrophy","volume":"423","author":"Bansal","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2024.102443_bib20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.tcb.2004.03.001","article-title":"Dysferlin and the plasma membrane repair in muscular dystrophy","volume":"14","author":"Bansal","year":"2004","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.omtn.2024.102443_bib21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1600-0854.2007.00573.x","article-title":"Dysferlin in Membrane Trafficking and Patch Repair","volume":"8","author":"Glover","year":"2007","journal-title":"Traffic"},{"key":"10.1016\/j.omtn.2024.102443_bib22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbrc.2011.08.105","article-title":"Characterization of zebrafish dysferlin by morpholino knockdown","volume":"413","author":"Kawahara","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2024.102443_bib23","doi-asserted-by":"crossref","first-page":"20831","DOI":"10.1073\/pnas.1307960110","article-title":"Dysferlin stabilizes stress-induced Ca2+ signaling in the transverse tubule membrane","volume":"110","author":"Kerr","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2024.102443_bib24","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1096\/fj.06-7659com","article-title":"From T-tubule to sarcolemma: damage-induced dysferlin translocation in early myogenesis","volume":"21","author":"Klinge","year":"2007","journal-title":"Faseb. J."},{"key":"10.1016\/j.omtn.2024.102443_bib25","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1242\/jcs.198861","article-title":"Dysferlin mediates membrane tubulation and links T-tubule biogenesis to muscular dystrophy","volume":"130","author":"Hofhuis","year":"2017","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.omtn.2024.102443_bib26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/hmg\/8.5.855","article-title":"Dysferlin is a plasma membrane protein and is expressed early in human development","volume":"8","author":"Anderson","year":"1999","journal-title":"Hum. Mol. Genet."},{"unstructured":"BioGPS GeneAtlas U133A, gcrma. biogps.org, Probeset: 218660_at. http:\/\/biogps.org\/#goto=genereport&id=8291.","key":"10.1016\/j.omtn.2024.102443_bib27"},{"key":"10.1016\/j.omtn.2024.102443_bib28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1600-0854.2011.01267.x","article-title":"Ferlins: Regulators of Vesicle Fusion for Auditory Neurotransmission, Receptor Trafficking and Membrane Repair","volume":"13","author":"Lek","year":"2012","journal-title":"Traffic"},{"key":"10.1016\/j.omtn.2024.102443_bib29","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.ajpath.2013.01.041","article-title":"Expression of myoferlin in human and murine carcinoma tumors: Role in membrane repair, cell proliferation, and tumorigenesis","volume":"182","author":"Leung","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2024.102443_bib30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.expneurol.2016.06.026","article-title":"Dysferlin function in skeletal muscle: Possible pathological mechanisms and therapeutical targets in dysferlinopathies","volume":"283","author":"C\u00e1rdenas","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.omtn.2024.102443_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1472-6807-14-3","article-title":"Crystal structures of the human Dysferlin inner DysF domain","volume":"14","author":"Sula","year":"2014","journal-title":"BMC Struct. Biol."},{"key":"10.1016\/j.omtn.2024.102443_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29184-1","article-title":"FerA is a Membrane-Associating Four-Helix Bundle Domain in the Ferlin Family of Membrane-Fusion Proteins","volume":"8","author":"Harsini","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2024.102443_bib33","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jmb.2019.04.006","article-title":"Structural Basis for the Distinct Membrane Binding Activity of the Homologous C2A Domains of Myoferlin and Dysferlin","volume":"431","author":"Harsini","year":"2019","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.omtn.2024.102443_bib34","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jmb.2008.04.046","article-title":"Solution Structure of the Inner DysF Domain of Myoferlin and Implications for Limb Girdle Muscular Dystrophy Type 2B","volume":"379","author":"Patel","year":"2008","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.omtn.2024.102443_bib35","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1101\/gr.198701","article-title":"Novel Protein Domains and Repeats in Drosophila melanogaster : Insights into Structure, Function, and Evolution","volume":"11","author":"Ponting","year":"2001","journal-title":"Genome Res."},{"key":"10.1016\/j.omtn.2024.102443_bib36","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1212\/01.wnl.0000204358.89303.81","article-title":"Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy","volume":"66","author":"Sinnreich","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2024.102443_bib37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.yexcr.2014.01.026","article-title":"Antisense-mediated exon skipping: Taking advantage of a trick from Mother Nature to treat rare genetic diseases","volume":"325","author":"Veltrop","year":"2014","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.omtn.2024.102443_bib38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3233\/JND-150109","article-title":"Exon 32 Skipping of Dysferlin Rescues Membrane Repair in Patients\u2019 Cells","volume":"2","author":"Barth\u00e9l\u00e9my","year":"2015","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2024.102443_bib39","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ejhg.2010.4","article-title":"Therapeutic exon skipping for dysferlinopathies?","volume":"18","author":"Aartsma-Rus","year":"2010","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2024.102443_bib40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/nat.2019.0788","article-title":"Antisense-Mediated Skipping of Dysferlin Exons in Control and Dysferlinopathy Patient-Derived Cells","volume":"30","author":"Verwey","year":"2020","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2024.102443_bib41","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.omtn.2018.10.004","article-title":"Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy","volume":"13","author":"Lee","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102443_bib42","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/acn3.96","article-title":"A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides","volume":"1","author":"Dominov","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.omtn.2024.102443_bib43","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/humu.24036","article-title":"The genetic profile of dysferlinopathy in a cohort of 209 cases: Genotype\u2013phenotype relationship and a hotspot on the inner DysF domain","volume":"41","author":"Izumi","year":"2020","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2024.102443_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120058","article-title":"In Silico Screening Based on Predictive Algorithms as a Design Tool for Exon Skipping Oligonucleotides in Duchenne Muscular Dystrophy","volume":"10","author":"Echigoya","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2024.102443_bib45","doi-asserted-by":"crossref","first-page":"W193","DOI":"10.1093\/nar\/gkab442","article-title":"eSkip-Finder: a machine learning-based web application and database to identify the optimal sequences of antisense oligonucleotides for exon skipping","volume":"49","author":"Chiba","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102443_bib46","doi-asserted-by":"crossref","first-page":"e1306","DOI":"10.1038\/cddis.2014.272","article-title":"Dysferlin regulates cell membrane repair by facilitating injury-triggered acid sphingomyelinase secretion","volume":"5","author":"Defour","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omtn.2024.102443_bib47","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1113\/JP285103","article-title":"On the role of dysferlin in striated muscle: membrane repair, t-tubules and Ca 2+ handling","volume":"602","author":"Quinn","year":"2024","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.omtn.2024.102443_bib48","first-page":"391","article-title":"Laser induced wounding of the plasma membrane and methods to study the repair process","volume":"125","author":"Jimenez","year":"2015"},{"key":"10.1016\/j.omtn.2024.102443_bib49","article-title":"Cell Membrane Repair Assay Using a Two-photon Laser Microscope","volume":"131","author":"Lee","year":"2018","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.omtn.2024.102443_bib50","doi-asserted-by":"crossref","first-page":"17092","DOI":"10.1074\/jbc.M601885200","article-title":"Absence of Dysferlin Alters Myogenin Expression and Delays Human Muscle Differentiation \u201cin\u00a0Vitro.\u201d","volume":"281","author":"de Luna","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2024.102443_bib51","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.nmd.2012.03.002","article-title":"Myogenesis in dysferlin-deficient myoblasts is inhibited by an intrinsic inflammatory response","volume":"22","author":"Cohen","year":"2012","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2024.102443_bib52","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/diseases6040085","article-title":"Cell-Based Methods for Determination of Efficacy for Candidate Therapeutics in the Clinical Management of Cancer","volume":"6","author":"Gordon","year":"2018","journal-title":"Diseases"},{"key":"10.1016\/j.omtn.2024.102443_bib53","doi-asserted-by":"crossref","first-page":"e4007","DOI":"10.1002\/cbf.4007","article-title":"Cell viability and cytotoxicity assays: Biochemical elements and cellular compartments","volume":"42","author":"Khalef","year":"2024","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.omtn.2024.102443_bib54","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/humu.21160","article-title":"Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping","volume":"31","author":"Wein","year":"2010","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2024.102443_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120058","article-title":"In Silico Screening Based on Predictive Algorithms as a Design Tool for Exon Skipping Oligonucleotides in Duchenne Muscular Dystrophy","volume":"10","author":"Echigoya","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2024.102443_bib56","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1212\/NXG.0000000000000036","article-title":"Genetic profile for suspected dysferlinopathy identified by targeted next-generation sequencing","volume":"1","author":"Izumi","year":"2015","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.omtn.2024.102443_bib57","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ymthe.2017.05.013","article-title":"Structure-Based Designed Nano-Dysferlin Significantly Improves Dysferlinopathy in BLA\/J Mice","volume":"25","author":"Llanga","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102443_bib58","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene Moxeparvovec: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2024.102443_bib59","first-page":"855","article-title":"Safety concerns surrounding AAV and CRISPR therapies in neuromuscular treatment","volume":"4","author":"Wilton-Clark","year":"2023","journal-title":"M\u00e9d."},{"key":"10.1016\/j.omtn.2024.102443_bib60","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.omtn.2024.102443_bib61","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","article-title":"Golodirsen for Duchenne muscular dystrophy","volume":"56","author":"Anwar","year":"2020","journal-title":"Drugs Today"},{"key":"10.1016\/j.omtn.2024.102443_bib62","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1358\/dot.2019.55.10.3045038","article-title":"Viltolarsen for the treatment of Duchenne muscular dystrophy","volume":"55","author":"Roshmi","year":"2019","journal-title":"Drugs Today"},{"key":"10.1016\/j.omtn.2024.102443_bib63","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1358\/dot.2021.57.12.3352740","article-title":"Casimersen for Duchenne muscular dystrophy","volume":"57","author":"Wilton-Clark","year":"2021","journal-title":"Drugs Today"},{"key":"10.1016\/j.omtn.2024.102443_bib64","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/13543784.2024.2313105","article-title":"Duchenne muscular dystrophy: promising early-stage clinical trials to watch","volume":"33","author":"Tang","year":"2024","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.omtn.2024.102443_bib65","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ymthe.2018.10.011","article-title":"Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates","volume":"27","author":"Lim","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102443_bib66","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112546119","article-title":"Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy","volume":"119","author":"Lim","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2024.102443_bib67","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3390\/ani13071223","article-title":"The Importance of Animal Models in Biomedical Research: Current Insights and Applications","volume":"13","author":"Dom\u00ednguez-Oliva","year":"2023","journal-title":"Animals"},{"key":"10.1016\/j.omtn.2024.102443_bib68","first-page":"179","article-title":"Optimizing exon skipping therapies for DMD","volume":"26","author":"Yokota","year":"2007","journal-title":"Acta Myol."},{"key":"10.1016\/j.omtn.2024.102443_bib69","doi-asserted-by":"crossref","first-page":"34501","DOI":"10.1039\/D0RA04978F","article-title":"In\u00a0vivo and in\u00a0vitro studies of antisense oligonucleotides\u00a0\u2013 a review","volume":"10","author":"Kilanowska","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.omtn.2024.102443_bib70","series-title":"Preclinical Animal Modeling in Medicine (IntechOpen)","article-title":"Duchenne Muscular Dystrophy Animal Models","author":"Egorova","year":"2022"},{"key":"10.1016\/j.omtn.2024.102443_bib71","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3390\/pharmaceutics15041130","article-title":"Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies","volume":"15","author":"Anwar","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2024.102443_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/currents.RRN1298","article-title":"Dysferlin-deficient immortalized human myoblasts and myotubes as a useful tool to study dysferlinopathy","volume":"4","author":"Philippi","year":"2012","journal-title":"PLoS Curr."},{"key":"10.1016\/j.omtn.2024.102443_bib73","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-1-0716-2772-3_11","article-title":"Morpholino-Mediated Exons 28\u201329 Skipping of Dysferlin and Characterization of Multiexon-skipped Dysferlin using RT-PCR, Immunoblotting, and Membrane Wounding Assay. In Muscular Dystrophy Therapeutics","volume":"2587","author":"Anwar","year":"2023","journal-title":"Methods Mol. Biol."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253124003305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253124003305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:26:13Z","timestamp":1762601173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253124003305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2162253124003305"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102443","relation":{},"ISSN":["2162-2531"],"issn-type":[{"type":"print","value":"2162-2531"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisense oligonucleotide-mediated exon 27 skipping restores dysferlin function in dysferlinopathy patient-derived muscle cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102443"}}